



Tufts Center for the Study of Drug Development

TUFTS UNIVERSITY

Impact REPORT

ANALYSIS AND INSIGHT INTO CRITICAL DRUG DEVELOPMENT ISSUES

Annual approvals for neglected diseases rose from 2.6 in 2000-08 to 5 in 2009-12

HIV/AIDS and malaria drugs accounted for 60% of approvals in 2009-12

- Annual R&D funding for neglected diseases grew rapidly from 2000 to 2007, but then leveled off at \$3 billion.
- From 2009 to 2012, development of drugs to treat neglected diseases focused on the “Big Three” – HIV/AIDS, malaria, and tuberculosis.
- Public-private partnerships accounted for 50% of new product approvals in 2009-12, up from 46% in 2000-08.
- The research-based industry’s share of sponsorship of neglected disease drug development increased to 44% in 2009-12, from 36% in 2000-08.
- To help combat neglected diseases, more than a dozen large pharmaceutical firms have pledged to donate 14 billion drug treatments to patients over a 10-year period.